NASDAQ:HTBX

Heat Biologics Stock Forecast, Price & News

$1.19

+0.01 (+0.85 %)

(As of 10/23/2020 12:00 AM ET)

Add

Compare

Today's Range

$1.18

Now: $1.19▼

$1.22

50-Day Range

$1.02

MA: $1.23▼

$1.41

52-Week Range

$0.20

Now: $1.19▼

$4.30

Volume53,940 shs

Average Volume17.05 million shs

Market Capitalization$176.79 million

P/E RatioN/A

Dividend YieldN/A

Beta0.43

Heat Biologics, Inc., a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness. Its TCAP product candidates include ImPACT platform technology that develops product candidates consist of live, allogeneic off-the-shelf genetically-modified, and irradiated human cancer cells; and Combination Pan-antigen Cytotoxic Therapy, a dual-acting immunotherapy designed to deliver T-cell activation and enhanced, and T-cell specific co-stimulation in a single treatment. The company is developing HS-110 that is in Phase 2 clinical trial in combination with Bristol-Myers Squibb's nivolumab (Opdivo) for the treatment of non-small cell lung cancer. Its preclinical trial product candidates include HS-130 for the treatment of non-muscle invasive bladder cancer; and PTX-35 and PTX-15 for treating tumors and hematologic malignancies. The company was founded in 2008 and is headquartered in Durham, North Carolina.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Heat Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.33, Heat Biologics has a forecasted upside of 180.1% from its current price of $1.19.
Amount of Analyst Coverage
Heat Biologics has only been the subject of 3 research reports in the past 90 days.

3.0 Community Rank

Outperform Votes
Heat Biologics has received 369 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Heat Biologics has received 253 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Heat Biologics has received 59.32% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Heat Biologics and other stocks. Vote “Outperform” if you believe HTBX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HTBX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Heat Biologics does not currently pay a dividend.
Dividend Growth
Heat Biologics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Heat Biologics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.50% of the stock of Heat Biologics is held by insiders.
Percentage Held by Institutions
Only 7.06% of the stock of Heat Biologics is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Heat Biologics are expected to decrease in the coming year, from ($0.20) to ($0.22) per share.
Price to Book Value per Share Ratio
Heat Biologics has a P/B Ratio of 3.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.30 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:HTBX

Previous Symbol

CUSIPN/A

CIK1476963

Webwww.heatbio.com

Phone919-240-7133

Employees30

Debt

Debt-to-Equity RatioN/A

Current Ratio7.66

Quick Ratio7.66

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$3.05 million

Price / Sales57.96

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.39 per share

Price / Book3.05

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-20,020,000.00

Net Margins-579.28%

Return on Equity-75.71%

Return on Assets-53.27%

Miscellaneous

Outstanding Shares148,561,000

Market Cap$176.79 million

Next Earnings Date11/20/2020 (Estimated)

OptionableNot Optionable

$1.19

+0.01 (+0.85 %)

(As of 10/23/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive HTBX News and Ratings via Email

Sign-up to receive the latest news and ratings for HTBX and its competitors with MarketBeat's FREE daily newsletter.

Heat Biologics (NASDAQ:HTBX) Frequently Asked Questions

How has Heat Biologics' stock price been impacted by Coronavirus?

Heat Biologics' stock was trading at $0.70 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, HTBX stock has increased by 70.0% and is now trading at $1.19.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Heat Biologics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heat Biologics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Heat Biologics.

When is Heat Biologics' next earnings date?

Heat Biologics is scheduled to release its next quarterly earnings announcement on Friday, November 20th 2020.
View our earnings forecast for Heat Biologics.

How were Heat Biologics' earnings last quarter?

Heat Biologics Inc (NASDAQ:HTBX) posted its earnings results on Friday, August, 7th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.08) by $0.03. The biopharmaceutical company had revenue of $0.59 million for the quarter, compared to the consensus estimate of $0.60 million. Heat Biologics had a negative return on equity of 75.71% and a negative net margin of 579.28%.
View Heat Biologics' earnings history.

When did Heat Biologics' stock split? How did Heat Biologics' stock split work?

Shares of Heat Biologics reverse split before market open on Monday, January 22nd 2018. The 1-10 reverse split was announced on Friday, January 19th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 19th 2018. An investor that had 100 shares of Heat Biologics stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for HTBX?

4 brokers have issued 1-year price targets for Heat Biologics' shares. Their forecasts range from $2.00 to $4.00. On average, they expect Heat Biologics' stock price to reach $3.33 in the next year. This suggests a possible upside of 180.1% from the stock's current price.
View analysts' price targets for Heat Biologics.

Are investors shorting Heat Biologics?

Heat Biologics saw a increase in short interest in the month of September. As of September 30th, there was short interest totaling 11,290,000 shares, an increase of 58.3% from the September 15th total of 7,130,000 shares. Based on an average daily trading volume, of 31,210,000 shares, the days-to-cover ratio is presently 0.4 days.
View Heat Biologics' Short Interest.

Who are some of Heat Biologics' key competitors?

Some companies that are related to Heat Biologics include AnaptysBio (ANAB), Zafgen (ZFGN), DiaMedica Therapeutics (DMCAF), Akouos (AKUS), Cara Therapeutics (CARA), Collegium Pharmaceutical (COLL), Humanigen (HGEN), Humanigen (HGEN), BioSpecifics Technologies (BSTC), Radius Health (RDUS), Eagle Pharmaceuticals (EGRX), ORIC Pharmaceuticals (ORIC), Legend Biotech (CALT), CymaBay Therapeutics (CBAY) and Emisphere Technologies (EMIS).
View all competitors.

What other stocks do shareholders of Heat Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heat Biologics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Vaxart (VXRT), BioNano Genomics (BNGO), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), ADMA Biologics (ADMA), Novan (NOVN) and VBI Vaccines (VBIV).

Who are Heat Biologics' key executives?

Heat Biologics' management team includes the following people:

Mr. Jeffrey Alan Wolf, Founder, Chairman, CEO & Pres (Age 56)
Dr. Jeff T. Hutchins, Chief Scientific Officer & COO (Age 60)
Mr. Robert J. Jakobs, VP of Fin., Sec. & Controller (Age 64)
Dr. Justin Stebbing M.D., M.A., FRCP, FRCPath, Ph.D., Chief Medical Advisor and Member of Scientific & Clinical Advisory Board
Colonel George E. Peoples Jr., M.D., FACS, Chief Medical Advisor

What is Heat Biologics' stock symbol?

Heat Biologics trades on the NASDAQ under the ticker symbol "HTBX."

Who are Heat Biologics' major shareholders?

Heat Biologics' stock is owned by many different retail and institutional investors. Top institutional investors include Strategic Wealth Management Group LLC (0.03%).
View institutional ownership trends for Heat Biologics.

Which institutional investors are buying Heat Biologics stock?

HTBX stock was purchased by a variety of institutional investors in the last quarter, including Strategic Wealth Management Group LLC.
View insider buying and selling activity for Heat Biologics.

How do I buy shares of Heat Biologics?

Shares of HTBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Heat Biologics' stock price today?

One share of HTBX stock can currently be purchased for approximately $1.19.

How big of a company is Heat Biologics?

Heat Biologics has a market capitalization of $176.79 million and generates $3.05 million in revenue each year. Heat Biologics employs 30 workers across the globe.

What is Heat Biologics' official website?

The official website for Heat Biologics is www.heatbio.com.

How can I contact Heat Biologics?

Heat Biologics' mailing address is 627 DAVIS DRIVE SUITE 400, MORRISVILLE NC, 27560. The biopharmaceutical company can be reached via phone at 919-240-7133 or via email at [email protected]

This page was last updated on 10/26/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings